ClinicalTrials.gg
RecruitingNCT07948928Updated Nov 19, 2026

EHR Alerts to Improve GLP-1 Medication and Continuous Glucose Monitor Prescribing in Primary Care

An interventional study of Our Practice Advisory (OPA) alert in Diabetes Mellitus, Type 2 and Diabetes Mellitus, sponsored by Montefiore Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Health services research

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,989
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 480 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Planned enrollment
68th of 2,961
2,989 · median 90
Started
2026
with 157 others
No phase
1,242 of 3,308
200 open now
Primary completion
2027-03
later than 222 of 478 live
Registered
3,301st of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 68th largest by planned enrollment of the 2,961 interventional ones that give a count, is one of 158 that started in 2026, is one of 1,242 with no phase, reaches primary completion later than 222 of the 478 other live ones, and was the 3,301st registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This randomized quality improvement study will evaluate whether pop-up alerts in the electronic health record (EHR) increase prescribing of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and continuous glucose monitors (CGMs) for eligible patients with diabetes. The study will be conducted at nine Montefiore Medical Group primary care sites. Primary care providers will be randomly assigned to either receive the alerts or not receive them. The alerts will remind providers that a patient is eligible for a GLP-1 RA, a CGM, or both, and will help them choose the option covered by the patient's insurance. Providers in both groups will use their own clinical judgment in deciding whether to prescribe. The study will use information already recorded in patients' medical records.

Read the detailed description

Primary care providers (physicians, physician assistants and nurse practitioners) are randomized 1:1, stratified by site type (teaching vs. non-teaching), prior GLP-1 RA prescribing, and eligible-patient volume. Approximately 121 providers will be randomized. The patients they see who meet eligibility criteria during the study period are the enrolled participants and are reflected in the enrollment count. Residents and their patients are excluded. For providers in the intervention arm, the alert is an Our Practice Advisory (OPA) in Epic that fires during qualifying in-person or telehealth primary care visits. Patients eligible for both a GLP-1 RA and a CGM trigger a single combined alert; patients eligible for only one trigger only that portion of the alert. Intervention-arm providers also receive education on using the alert. Outcomes are analyzed at the patient level using only each patient's first qualifying visit. The analysis uses mixed-effects logistic regression with a random effect for provider.

Note: The Albert Einstein College of Medicine Institutional Review Board (IRB) determined this quality improvement project does not meet the definition of human subjects research. An IRB determination letter is on file with this registration.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus

Keywords

  • Clinical Decision Support
  • GLP-1 Receptor Agonist
  • Continuous Glucose Monitoring (CGM)
  • Rapid-cycle Randomized Quality Improvement (QI)
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet Klompas definition of diabetes
  • Has at least one primary care visit, in-person or telehealth, during the study period
  • Is covered by Medicare or Medicaid

Additional inclusion criteria for the GLP-1 portion of the OPA alert:

  • GLP-1 component: ≥ 9 on most recent lab test in the past 12 months and a ≥ 25) OR BMI ≥ 30, and no GLP-1 prescription in the past 12 months

Additional inclusion criteria for the CGM portion of the OPA alert:

  • CGM component: Insulin prescription in the past 12 months and no CGM prescription in the past 12 months

Exclusion criteria

Exclusion Criteria:

  • Patients seen by residents during their first visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,989 participants (estimated)

Study arms

  • Experimental
    Our Practice Advisory (OPA) Alert

    Education will be provided on the use of the alerts to PCPs in the intervention group. Providers will continue using clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients.

    Other: Our Practice Advisory (OPA) alert

  • No intervention
    Usual Care (UC)

    Providers continue usual care, with no alert. Providers will use clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients.

Interventions

  • OtherOur Practice Advisory (OPA) alert

    Electronic Health Record (EHR) Our Practice Advisory, a pop-up electronic notification for clinical staff available at the time of a clinical encounter in the electronic medical record, recommending the insurance-preferred GLP-1 and/or a CGM, plus education for providers on using the alerts

06

What researchers measure

Primary outcomes

  1. Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication

    The percentage of patients meeting the GLP-1 RA alert eligibility criteria who are newly prescribed a GLP-1 RA covered by their insurance, as documented in the electronic health record. GLP-1 RAs not covered by the patient's insurance are not counted. Each patient's first qualifying visit during the study period is analyzed.

    Time frame: At the first qualifying primary care visit during the study period, up to 3 months

  2. Percentage of Eligible Patients Newly Prescribed a CGM

    The percentage of patients meeting the CGM alert eligibility criteria who are newly prescribed a continuous glucose monitor (CGM), as documented in the electronic health record. Each patient's first qualifying visit during the study period is analyzed.

    Time frame: At the first qualifying primary care visit during the study period, up to 3 months

Secondary outcomes

  1. Provider Response to the OPA alert

    For the OPA arm only, providers interaction with the OPA alert will be evaluated based on the percentage of time the OPA alert fired and was either: ignored, declined, and approved. The unit of analysis are patients. Each nominal categorical variable will be summarized.

    Time frame: Throughout the study period, up to 3 months

  2. Reasons for Declining the OPA alert

    Among alert firings declined by providers in the OPA Alert arm, the percentage for each decline reason selected in the electronic health record will be summarized. The reasons are: Defer to Next Visit; Patient Declines; Chart Review Only; Does Not Meet Criteria; Financial Limitations; Treatment Ineffective; Patient Can't Tolerate. The unit of analysis are patients.

    Time frame: Throughout the study period, up to 3 months

  3. Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication by Patient Characteristics

    Primary outcome evaluated by patient Body Mass Index (BMI) category, HbA1c category, Insulin status, Age group, Sex, and Race/Ethnicity. The unit of analysis are patients.

    Time frame: Throughout the study period, up to 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023 Jul 15;402(10397):203-234. doi: 10.1016/S0140-6736(23)01301-6. Epub 2023 Jun 22. PubMed 37356446 ↗
  • Davidson JA. The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010 Dec;85(12 Suppl):S3-4. doi: 10.4065/mcp.2010.0466. Epub 2010 Nov 24. No abstract available. PubMed 21106869 ↗
  • Pilla SJ, Segal JB, Maruthur NM. Primary Care Provides the Majority of Outpatient Care for Patients with Diabetes in the US: NAMCS 2009-2015. J Gen Intern Med. 2019 Jul;34(7):1089-1091. doi: 10.1007/s11606-019-04843-9. No abstract available. PubMed 30719646 ↗
  • American Diabetes Association Professional Practice Committee for Diabetes*. 7. Diabetes Technology: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Suppl 1):S150-S165. doi: 10.2337/dc26-S007. PubMed 41358889 ↗
  • Nemlekar PM, Hannah KL, Green CR, Norman GJ. Association Between Adherence, A1C Improvement, and Type of Continuous Glucose Monitoring System in People with Type 1 Diabetes or Type 2 Diabetes Treated with Intensive Insulin Therapy. Diabetes Ther. 2024 Mar;15(3):639-648. doi: 10.1007/s13300-023-01529-8. Epub 2024 Jan 30. PubMed 38289464 ↗
  • Porter M, Fonda S, Swigert T, Ehrhardt N. Real-Time Continuous Glucose Monitoring to Support Self-Care: Results from a Pilot Study of Patients With Type 2 Diabetes. J Diabetes Sci Technol. 2022 Mar;16(2):578-580. doi: 10.1177/19322968211053886. Epub 2021 Oct 25. No abstract available. PubMed 34696604 ↗
  • Ehrhardt N, Al Zaghal E. Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring. J Diabetes Sci Technol. 2019 Mar;13(2):271-275. doi: 10.1177/1932296818790994. Epub 2018 Aug 1. PubMed 30066574 ↗
  • Martens TW, Parkin CG. How use of continuous glucose monitoring can address therapeutic inertia in primary care. Postgrad Med. 2022 Aug;134(6):576-588. doi: 10.1080/00325481.2022.2080419. Epub 2022 May 27. PubMed 35584802 ↗
  • Martens T, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, Pop-Busui R, Philis-Tsimikas A, Bao S, Umpierrez G, Davis G, Kruger D, Bhargava A, Young L, McGill JB, Aleppo G, Nguyen QT, Orozco I, Biggs W, Lucas KJ, Polonsky WH, Buse JB, Price D, Bergenstal RM; MOBILE Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021 Jun 8;325(22):2262-2272. doi: 10.1001/jama.2021.7444. PubMed 34077499 ↗
  • Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, McGill JB, Polonsky W, Price D, Aronoff S, Aronson R, Toschi E, Kollman C, Bergenstal R; DIAMOND Study Group. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med. 2017 Sep 19;167(6):365-374. doi: 10.7326/M16-2855. Epub 2017 Aug 22. PubMed 28828487 ↗
  • Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes. JAMA. 2021 Jun 8;325(22):2273-2284. doi: 10.1001/jama.2021.6530. PubMed 34077502 ↗
  • Reaven PD, Newell M, Rivas S, Zhou X, Norman GJ, Zhou JJ. Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration. Diabetes Care. 2023 Apr 1;46(4):854-863. doi: 10.2337/dc22-2189. PubMed 36807492 ↗
  • Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024 Jan 29;384:e076410. doi: 10.1136/bmj-2023-076410. PubMed 38286487 ↗
  • Ren X, Hua H, Wu Y, Zhang W, Long X, Bai Y, Cheng N. Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis. Sci Rep. 2025 Jul 6;15(1):24103. doi: 10.1038/s41598-025-09807-0. PubMed 40619508 ↗
  • Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 May;132(6):2131-57. doi: 10.1053/j.gastro.2007.03.054. PubMed 17498508 ↗
  • Rosen CJ, Ingelfinger JR. GLP-1 Receptor Agonists. N Engl J Med. 2026 Apr 2;394(13):1313-1324. doi: 10.1056/NEJMra2500106. PubMed 41931049 ↗
  • Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. PubMed 27295427 ↗
  • Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. PubMed 27633186 ↗
  • Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. PubMed 31189511 ↗
  • Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24. PubMed 38785209 ↗
  • Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA; Clinical Guidelines Committee of the American College of Physicians; Fitterman N, Balzer K, Boyd C, Humphrey LL, Iorio A, Lin J, Maroto M, McLean R, Mustafa R, Tufte J. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018 Apr 17;168(8):569-576. doi: 10.7326/M17-0939. Epub 2018 Mar 6. PubMed 29507945 ↗
  • Qaseem A, Obley AJ, Shamliyan T, Hicks LA, Harrod CS, Crandall CJ; Clinical Guidelines Committee of the American College of Physicians; Balk EM, Cooney TG, Cross JT Jr, Fitterman N, Lin JS, Maroto M, Miller MC, Shekelle P, Tice JA, Tufte JE, Etxeandia-Ikobaltzeta I, Yost J. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2024 May;177(5):658-666. doi: 10.7326/M23-2788. Epub 2024 Apr 19. PubMed 38639546 ↗
  • American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Suppl 1):S183-S215. doi: 10.2337/dc26-S009. PubMed 41358900 ↗
  • Vigersky RA, Fish L, Hogan P, Stewart A, Kutler S, Ladenson PW, McDermott M, Hupart KH. The clinical endocrinology workforce: current status and future projections of supply and demand. J Clin Endocrinol Metab. 2014 Sep;99(9):3112-21. doi: 10.1210/jc.2014-2257. Epub 2014 Jun 18. PubMed 24940655 ↗
  • Horwitz LI, Kuznetsova M, Jones SA. Creating a Learning Health System through Rapid-Cycle, Randomized Testing. N Engl J Med. 2019 Sep 19;381(12):1175-1179. doi: 10.1056/NEJMsb1900856. No abstract available. PubMed 31532967 ↗
  • Horwitz LI, Krelle HA. Using Rapid Randomized Trials to Improve Health Care Systems. Annu Rev Public Health. 2023 Apr 3;44:445-457. doi: 10.1146/annurev-publhealth-071521-025758. Epub 2022 Nov 18. PubMed 36400154 ↗
  • Pletcher MJ, Lo B, Grady D. Randomized Quality Improvement Trials: An Overview and Proposed Framework for Ethical Oversight. Ann Intern Med. 2026 Oct;179(10):1444-1452. doi: 10.7326/ANNALS-26-00221. Epub 2026 Aug 18. PubMed 42607308 ↗
  • Hemming K, Taljaard M. Key considerations for designing, conducting and analysing a cluster randomized trial. Int J Epidemiol. 2023 Oct 5;52(5):1648-1658. doi: 10.1093/ije/dyad064. PubMed 37203433 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

Of 2,072 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 4 months is below that.

Counting every sponsor, half of 2,249 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 19, 2026
StartEst.
Nov 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948928
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Shivani Agarwal, MD, MPH
Contact
shagarwa@montefiore.org
844-556-6683 ext. 32
Silvie Colman
Contact
scolman@montefiore.org
Shivani Agarwal, MD, MPH
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion